Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
Open Access
- 5 October 2018
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 33 (3) , 785-790
Abstract
No abstract availableFunding Information
- Associazione Italiana per la Ricerca sul Cancro (16952)
This publication has 14 references indexed in Scilit:
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasmsLeukemia, 2017
- Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignanciesJournal of Cancer Research and Clinical Oncology, 2017
- Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantationBlood, 2017
- Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective studyAnnals of Oncology, 2017
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesNew England Journal of Medicine, 2016
- Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationJournal of Clinical Oncology, 2016
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesLeukemia, 2015
- The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active TetramersCancer Cell, 2014
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013